Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Kuros Biosciences AG
/ Key word(s): Regulatory Approval
Schlieren (Zurich), Switzerland, November 28, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that MagnetOs Flex Matrix has been cleared for use in the interbody space by the U.S. Food and Drug Administration (FDA). As a result, it can now be used in any interbody space (cervical, thoracic, lumbar); and in any cage approved for use with a bone void filler. With interbody cages being used in almost half of the estimated 1.5 million instrumented spinal fusion procedures conducted annually in the USA, this news is especially significant for surgeons.1,2 MagnetOs Flex Matrix is uniquely well suited to interbody applications. Due to its excellent granule retention, it stays strong yet flexible even when wet - for easy placement either through a funnel or packed directly into any cage, of any size. MagnetOs Flex Matrix is the first Kuros product to receive interbody clearance, having already been cleared by the FDA for use in posterolateral fusions. Due to its unique fibrillar and flexible structure, this open matrix bone graft promotes bone growth even in soft tissue by optimizing the effect of Kuros’ established NeedleGripTM surface technology. Chris Fair, Chief Executive Officer of Kuros, said: "This is an important milestone for our company, as well as for the surgical community. With this clearance, we have a substantial commercial opportunity to re-engage with surgeons who were previously unable to use our MagnetOs Flex Matrix product on-label for interbody procedures. Kuros will continue to develop our research and technology – thus further demonstrating how we are continuing to meet our strategic goals for the benefit of patients and our investors."
For further information, please contact:
About MagnetOs U.S. Indications Statement About Kuros Biosciences Forward Looking Statements
1. iData Research, How Many Spinal Fusions are Performed Each Year in the United States? https://idataresearch.com/how-many-instrumented-spinal-fusions-are-performed-each-year-in-the-united-states/, accessed November 2023 2. AcuityMD, procedure numbers estimated by CPT code Q4 2022-Q3 2023 3. Duan, et al. eCM. 2019;37:60-73 4. Van Dijk, et al. eCM. 2021;41:756-73 5. Van Dijk, et al. JOR Spine. 2018;e1039 6. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090 7. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276–E287 8. Data on file *In large animal models †Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com ‡MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft §For a 510(k)-cleared synthetic bone graft. ¶MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion. Additional features: File: Press Release (PDF)
End of Media Release |
Language: | English |
Company: | Kuros Biosciences AG |
Wagistrasse 25 | |
8952 Schlieren | |
Switzerland | |
Phone: | +41 44 733 4747 |
Fax: | +41 44 733 4740 |
E-mail: | info@kurosbio.com |
Internet: | www.kurosbio.com |
ISIN: | CH0325814116 |
Valor: | 32581411 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1779901 |
End of News | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: